1001123-94-9

Basic information

• Product Name: methyl 2-(4-chlorophenyl)-4-methyl-4-nitropentanoate
• Synonyms: methyl 2-(4-chlorophenyl)-4-methyl-4-nitropentanoate
• CAS NO: 1001123-94-9
• Molecular Weight: 285.727
• Mol File: 1001123-94-9.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: methyl 2-(4-chlorophenyl)-4-methyl-4-nitropentanoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 2-(4-chlorophenyl)-4-methyl-4-nitropentanoate(1001123-94-9)
• EPA Substance Registry System: methyl 2-(4-chlorophenyl)-4-methyl-4-nitropentanoate(1001123-94-9)

Safety Data

• Hazardous Substances Data: 1001123-94-9(Hazardous Substances Data)

Upstream product

• 1878-66-6 4-chlorophenylacetic Acid 
• 109135-06-0 methyl 2-(4-chlorophenyl)-3-hydroxypropanoate 
• 52449-43-1 (4-chloro-phenyl)-acetic acid methyl ester 
• 79-46-9 2-nitropropane 
• 50415-59-3 methyl 2-(4-chlorophenyl)acrylate 

Downstream Products

• 1001123-96-1 3-(4-chlorophenyl)-5,5-dimethylpyrrolidin-2-one 
• 1289642-24-5 C₁₃H₁₈ClNO₂ 

Relevant articles and documents

Discovery of dihydrothieno- and dihydrofuropyrimidines as potent pan Akt inhibitors

Herein we report the discovery and synthesis of a novel series of dihydrothieno- and dihydrofuropyrimidines (2 and 3) as potent pan Akt inhibitors. Utilizing previous SAR and analysis of the amino acid sequences in the binding site we have designed inhibi

HYDROXYLATED AND METHOXYLATED CYCLOPENTA [D] PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS

The present invention provides compounds, including resolved enantiomers, resolved diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula (I). Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.

DIHYDROTHIENO PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS

The present invention provides compounds, including resolved enantiomers, diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula (I): Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.